Laman UtamaAMRN • NASDAQ
add
Amarin Corporation PLC
Tutup sebelumnya
$14.12
Julat hari
$13.78 - $14.07
Julat tahun
$7.08 - $20.90
Permodalan pasaran
285.72J USD
Bilangan Purata
91.39K
Nisbah P/E
-
Hasil dividen
-
Dalam berita
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (USD) | Dis 2025info | Perubahan T/T |
|---|---|---|
Hasil | 49.22J | -21.00% |
Perbelanjaan pengendalian | 25.43J | -40.80% |
Pendapatan bersih | -1.22J | 97.48% |
Margin untung bersih | -2.49 | 96.81% |
Pendapatan bagi setiap syer | 0.01 | 102.50% |
EBITDA | -1.39J | 90.90% |
Kadar cukai berkesan | -43.66% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (USD) | Dis 2025info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 302.59J | 2.84% |
Jumlah aset | 670.78J | -2.13% |
Jumlah liabiliti | 211.49J | 6.19% |
Jumlah ekuiti | 459.28J | — |
Syer tertunggak | 20.81J | — |
Harga kepada buku | 0.64 | — |
Pulangan pada aset | -0.85% | — |
Pulangan pada modal | -1.21% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (USD) | Dis 2025info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -1.22J | 97.48% |
Tunai daripada operasi | — | — |
Tunai daripada pelaburan | — | — |
Tunai daripada pembiayaan | — | — |
Perubahan bersih dalam tunai | — | — |
Aliran tunai bebas | — | — |
Perihal
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa, a prescription grade omega-3 fatty acid.
In July 2012, their lead-candidate drug named Vascepa received FDA-approval, competing against GlaxoSmithKline's Lovaza. Wikipedia
Diasaskan
1 Mac 1989
Ibu pejabat
Tapak web
Pekerja
275
